Browse > Article
http://dx.doi.org/10.4333/KPS.2002.32.2.119

Determination of Terazocin in Human Plasma by Liquid Chromatography and Bioequivalence Study of Teratonin® Tablets  

Cho, Eun-Sook (College of Pharmacy and Pharmaceutical Research Center, Dongduk Women's University)
Kang, Sung-Ha (Department of Clinical Pathology, Chunchon Sacred Heart Hospital, Hallym University)
Chun, In-Koo (College of Pharmacy and Pharmaceutical Research Center, Dongduk Women's University)
Publication Information
Journal of Pharmaceutical Investigation / v.32, no.2, 2002 , pp. 119-125 More about this Journal
Abstract
A rapid, selective and reproducible high-performance liquid chromatographic method has been developed for the determination of terazocin in human plasma. Terazocin plus the internal standard, prazocin hydrochloride, were extracted from alkalified plasma with tert-butylmethyl ether, back-extracted into 0.05% phosphoric acid. Fifty ${\mu}l-portions$ of extract were injected onto a octadecylsilane column and eluted with a mixture of acetonitrile, water and triethylamine (30 : 70 : 0.1 v/v, adjusted to pH 5.0 with dilute phosphoric acid) at a flow rate of 1.0 ml/min. The fluorescence intensity of column eluents was monitored at excitation wavelength of 250 nm and emission wavelength of 370 nm. No interference peaks were observed. The practical limit of quantitation was 5 ng/ml for terazocin. The average intraday and interday coefficients of variation were 4.15 and 3.54%, respectively. Also intraday and interday precisions over the range $5{\sim}60\;ng/ml$ were $0.49{\sim}2.92\;and\;0.38{\sim}5.12%$, respectively. The bioequivalence of two terazosin tablets, the $Hytrine^{\circledR}$ (Il Yang Pharmaceutical Co., Ltd.) and the $Teratonin^{\circledR}$ (Sam-A Pharmaceutical Co., Ltd.), was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). Sixteen healthy male volunteers $(24.6{\pm}2.0\;years\;old)$ were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one tablet containing 2 mg of terazosin was orally administered, blood was taken at predetermined time intervals and the concentration of terazosin in plasma was determined with a HPLC method using spectrofluorometric detector. AUC was calculated by the linear trapezoidal method. $C_{max}\;and\;T_{max}$ were compiled from the plasma drug concentration-time data. Analysis of variance (ANOVA) was utilized for the statistical analysis of the parameters. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between the two preparations were 0.21 %, 5.53% and 8.82%, respectively. The powers $(1-{\beta})\;for\;AUC_t,\;C_{max}\;and\;T_{max}$ were >99%, 97.49%, and 33.26%, respectively. Minimum detectable differences $({\Delta},\;%)\;at\;{\alpha}=0.1\;and\;1-{\beta}=0.8$ and the 90% confidence intervals were all less than ${\pm}20%$ except for $T_{max}.\;AUC_t\;and\;C_{max}$ met the criteria of KDFA for bioequivalence, indicating that $Teratonin^{circledR}$ tablets are bioequivalent to $Hytrine^{circledR}$ tablets.
Keywords
Bioequivalence; Terazosin tablets; $Hytrine^{\circledR}$; $Teratonin^{\circledR}$; HPLC;
Citations & Related Records
연도 인용수 순위
  • Reference
1 H. Lepor, W.O. Williford, M.J. Barry, M.K. Brawer, C.M. Dixon, G. Gormley, C. Haakenson, M. Machi, P. Narayan and R.J. Padley, The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia, New Eng. J. Med., 335, 533-539 (1996)   DOI   ScienceOn
2 J J. McNeil, O.H. Drummer, K. Raymond, E.L. Conway and W.J. Louis, The influence of food on the oral bioavailability of terazosin, Br. J. Clin. Pharmacol., 32, 775-776 (1991)
3 R.C. Sonders, Pharmacokinetics of terazosin, Am. J. Med., 80 (Suppl. 5B), 20-24 (1986)
4 S.J. Kim, D.K. Lim, I.J. Oh, S.C. Shin, H.S. Park, J.D. Moon and Y.B. Lee, Bioequivalence of Terasin tablet to Hytrine tablet (terazosin 2 mg). J. Kor. Pharm. Sci., 29, 61-66 (1999)
5 Y.J. Lee, J.H. Choi, J.H., S.H. Song, C.H. Seo, D.S. Kim, I.S. Park, K.H. Choi, H.K. Na, S.J. Chung, M.H. Lee and C.K. Shim, Development of K-BEtest_, a computer program for the analysis of bioequivalence, J. Kor. Pharm. Sci., 28, 223-229 (1998)
6 J.L. Pool, E.G. Nelson, A.A. Taylor and J.R. Mitchell, Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension, Br. J. Clin. Pract. Symp., 54, 9-14 (1987)
7 S. Titmarsh and J.P. Monk, Terazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension, Drugs, 33, 461-477 (1987)   DOI   ScienceOn
8 J.C. Somberg, R. Achari and A.R. Laddu, Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events, Am. Heart J., 122, 901-905 (1991)   DOI   ScienceOn
9 R. Achari and A. Laddu, Terazosin: A new alpha adreno- ceptor blocking drug, J. Clin. Pharmacol., 32, 520-523 (1992)   DOI
10 P.G. Fabricius, P. Weizert, U. Dunzendorfer, J.M. Hannaford and C. Maurath, Efficacy of once a day terazosin in benign prostatic hyperplasia: a randamised, double blind placebo controlled clinical trial, Prostate Suppl., 3, 85-93 (1990)
11 Y.G. Yee, P.C. Rubin and P. Meffin, Prazosin determination by high-pressure liquid chromatography using fluorescence detection, J. Chromatogr., 172, 313-318 (1979)   DOI   ScienceOn
12 H. Lepor, G. Knapp-Maloney and H. Sunshine, A dose titration study evauating terazosin, a selective, once-a-day $\alpha_1$-blocker for the treatment of symptomatic benign prostatic hyperplasia, J. Urol., 144, 1393-1398 (1990)   DOI
13 P. Jungers, D. Ganeval, N. Pertuiset and P. Chauveau, Influence of renal insufficiency on the pharmacokinetics and pharmaco- dynamics of terazosin, Am. J. Med., 80 (suppl. 5B), 94-99 (1986)
14 J.J. McNeil, O.H. Drummer, E.L. Conway, B.S. Workman and W.J. Louis, Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin, J. Cardiova- scular Pharmacol., 10, 168-175 (1987)   DOI   ScienceOn
15 S.E. Patterson, Rapid and sensitive analysis of terazosin in plasma, peritoneal dialysis solution, and urine using high-performance liquid chromatography with fluorescence detec- tion, J. Chromatogr., 311, 206-212 (1984)   DOI   ScienceOn
16 S.E. Patterson, Terazocin kinetics after oral and intravenous doses, Clin. Pharmacol. Ther., 38, 423-427 (1985)   DOI   ScienceOn
17 R.K. Bhamra, R.J. Flanagan and D.W. Holt, High performance liquid chromatographic measurement of prazosin and terazosin in biological fluids, J. Chromatogr., 380, 216-221 (1986)   DOI   ScienceOn
18 N. Aoyagi, Bioequivalence test for oral dosage forms in Japan. Proceedings of the 44th Convention of The Pharmaceutical Society of Korea, 1995, pp. 50
19 K. Taguchi, R.F. Schaefers and M.C. Michel, Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics, Br. J. Clin. Pharmacol., 45, 49-55 (1998)   DOI   ScienceOn
20 E.E. Samara, B. Hosmane, C. Locke, C. Eason, J. Cavanaugh and G.R. Granneman, Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride, J. Clin. Pharmacol., 36, 1169-1178 (1996)   DOI   ScienceOn